Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16951969 | 0.83 | MGLL (0.36) | MGLLALDH1A1GRM5KDM1AHPGDS | |
| SCHEMBL16961695 | 0.79 | ALDH1A1 (0.39) | MGLLALDH1A1GRM5KDM1AHPGDS | |
| SCHEMBL21164288 | 0.78 | MGLL (0.38) | MGLLALDH1A1GRM5AHRKDM1A | |
| SCHEMBL21135650 | 0.76 | MGLL (0.40) | MGLLALDH1A1GRM5KDM1AKCNH2 | |
| SCHEMBL16959946 | 0.76 | ALDH1A1 (0.37) | MGLLALDH1A1GRM5KDM1AHPGDS | |
| SCHEMBL10472613 | 0.75 | MGLL (0.36) | MGLLALDH1A1AHR | |
| SCHEMBL15958517 | 0.75 | ALDH1A1 (0.42) | MGLLALDH1A1GRM5KDM1AHPGDS | |
| SCHEMBL7470616 | 0.74 | GPR84 (0.40) | ALDH1A1AHR | |
| SCHEMBL202404 | 0.74 | ALDH1A1 (0.61) | ALDH1A1GRM5KDM1AHPGDSPGR | |
| SCHEMBL6682154 | 0.74 | ALDH1A1 (0.41) | MGLLALDH1A1GRM5KDM1AHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 444 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390246-A1 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-12-07 | — | — | US | disclosed |
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230105307-A1 | Identification of Stabilizers of Multimeric Proteins | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-04-06 | — | — | US | disclosed |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | HISTOGEN, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220202837-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-30 | — | — | US | disclosed |
| US-11337935-B2 | Identification of stabilizers of multimeric proteins | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-05-24 | — | — | US | disclosed |
| US-11268952-B2 | Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof | FIRMENICH INCORPORATED (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3935042-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | Conatus Pharmaceuticals, Inc. (US) | 2022-01-12 | — | — | EP | disclosed |
| US-11136362-B2 | Peptide modulators of specific calcineurin protein-protein interactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-10-05 | — | — | US | disclosed |
| US-11129902-B2 | Enhanced SN-38 anticancer agent | Alhamadsheh, Mamoun M. (US) | 2021-09-28 | — | — | US | disclosed |
| EP-0890101-A1 | SELECTIVELY N-ALKYLATED PEPTIDOMIMETIC COMBINATORIAL LIBRARIES AND COMPOUNDS THEREIN | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1999-01-13 | — | — | EP | disclosed |
| US-5840500-A | OPIOD RECEPTORS AS ANALGESICS AND CENTRALLY ACTING PAIN KILLERS | TREGA BIOSCIENCES, INC. (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0863877-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1998034115-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998034111-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998002741-A9 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | — | 1998-05-22 | — | — | WO | disclosed |
| WO-1998011129-A1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INCORPORATED (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998002741-A1 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-01-22 | — | — | WO | disclosed |
| WO-1997033174-A1 | SELECTIVELY N-ALKYLATED PEPTIDOMIMETIC COMBINATORIAL LIBRARIES AND COMPOUNDS THEREIN | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1997-09-12 | — | — | WO | disclosed |
| WO-1997016428-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230105307-A1 | Identification of Stabilizers of Multimeric Proteins | TTR, HSPBP1, HSPH1 | MGLL 4072/4885ALDH1A1 3493/4885CYP19A1 4872/4885 |
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | MGLL 2290/4885ALDH1A1 2161/4885CYP19A1 682/4885 |
| US-20220202837-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | PTMS, QPCT, ANPEP | MGLL 2030/4885ALDH1A1 3718/4885CYP19A1 4554/4885 |
| US-11337935-B2 | Identification of stabilizers of multimeric proteins | TTR, HSPBP1, HSPH1 | MGLL 4072/4885ALDH1A1 3493/4885CYP19A1 4872/4885 |
| US-20230390246-A1 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions | TTR, PRNP, APP | MGLL 3622/4885ALDH1A1 3846/4885CYP19A1 4578/4885 |
| US-11129902-B2 | Enhanced SN-38 anticancer agent | LENG8, TSG101, CD47 | MGLL 2018/4885ALDH1A1 3116/4885CYP19A1 3674/4885 |
| US-11268952-B2 | Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof | TAS2R40, TAS1R2, TAS1R1 | MGLL 1075/4885ALDH1A1 1037/4885CYP19A1 4519/4885 |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | CASP1, CASP3, CASP7 | MGLL 2290/4885ALDH1A1 2161/4885CYP19A1 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.